JAZZ beat EPS expectations by 182.78%
May 06, 2025, 10:31 PM
0.00%
What does JAZZ do
Jazz Pharmaceuticals Plc, headquartered in Dublin, focuses on developing treatments for narcolepsy, oncology, pain, and psychiatry, employing 2,800 staff since its IPO in 2012. Key products include Xywav, Xyrem, and Defitelio.
Jazz Pharmaceuticals plc (JAZZ) reported a positive EPS surprise in its most recent quarterly earnings. For the most recent quarter, Jazz Pharmaceuticals plc's actual EPS was $1.68, beating the estimate of $4.75 per share, resulting in a 182.78% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.